The DOI matches its Crossref record; 88 of the 89 references it cites were found in a registry or an index, and 1 are not checked yet.
Metformin Therapy and Risk of Cancer in Patients with Type 2 Diabetes: Systematic Review
Open accessAbstract
AIMS/HYPOTHESIS: Diabetes treatments were related with either an increased or reduced risk of cancer. There is ongoing debate about a potential protective action of metformin. To summarize evidence on the association between metformin and risk of cancer and cancer mortality in patients with diabetes. DATA SOURCE: MEDLINE and EMBASE (January 1966-April 2012). We selected randomized studies comparing metformin and other hypoglycaemic agents and observational studies exploring the association between exposure to metformin and cancer. Outcomes were cancer mortality, all malignancies and site-specific cancers. RESULTS: Of 25307 citations identified, 12 randomized controlled trials (21,595 patients) and 41 observational studies (1,029,389 patients) met the inclusion criteria. In observational studies there was a significant association of exposure to metformin with the risk of cancer death [6 studies, 24,410 patients, OR:0.65, 95%CI: 0.53-0.80], all malignancies [18 studies, 561,836 patients, OR:0.73, 95%CI: 0.61-0.88], liver [8 studies, 312,742 patients, OR:0.34; 95%CI: 0.19-0.60] colorectal [12 studies, 871,365 patients, OR:0.83, 95%CI: 0.74-0.92], pancreas [9 studies, 847,248 patients, OR:0.56, 95%CI: 0.36-0.86], stomach [2 studies, 100701 patients, OR:0.83, 95%CI: 0.76-0.91], and esophagus cancer [2 studies, 100694 patients, OR:0.90, 95%CI: 0.83-0.98]. No significant difference of risk was observed in randomized trials. Metformin was not associated with the risk of: breast cancer, lung cancer, ovarian cancer, uterus cancer, prostate cancer, bladder cancer, kidney cancer, and melanoma. CONCLUSIONS/INTERPRETATION: Results suggest that Metformin might be associated with a significant reduction in the risk of cancer and cancer-related mortality. Randomized trials specifically designed to evaluate the efficacy of metformin as an anticancer agent are warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“long-term use of metformin in type 2 diabetes patients has been linked to a decline in tumor incidence and a reduced rate of cancer-related deaths.192–196”
From Drug repurposing for cancer therapy (2024) · cites this paper as [193]
Experimental — accuracy not yet measuredIn the citing paper
“Furthermore, retrospective clinical studies have found that metformin use is associated with improved cancer outcomes, reductions in cancer incidence, and decreased cancer mortality (Evans et al., 2005; Franciosi et al., 2013; Gandini et al., 2014; Lee et al., 2012; Noto et al., 2012).”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Franciosi et al., 2013
In the citing paper
“this finding has subsequently been confirmed in several other studies(7–10).”
In the citing paper
“Originally introduced for the treatment of diabetes, metformin is now gaining attention as a potential anti-cancer agent (7–10) (Figure 1).”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652
Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1. The Cochrane Collaboration
Higgins, J., Green, S. R., & Higgins, J. (2008) · Cited by 5,544
Cochrane Handbook for Systematic Reviews of Interventions
Tarsilla, M. (2010) · Journal of MultiDisciplinary Evaluation · doi:10.56645/jmde.v6i14.284 · Cited by 5,232
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Metformin and reduced risk of cancer in diabetic patients
Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005) · BMJ · doi:10.1136/bmj.38415.708634.f7 · Cited by 2,388
Case-Control Studies: Design, Conduct, Analysis.
Youkeles, L., & Schlesselman, J. J. (1983) · Journal of the American Statistical Association · doi:10.2307/2288156 · Cited by 2,358
Drug delivery with carbon nanotubes for in vivo cancer treatment
Liu, Z., Chen, K., Davis, C. R., Sherlock, S. P., Cao, Q., Chen, X. S., & Dai, H. (2008) · PubMed · doi:10.48550/arxiv.0808.2070 · Cited by 2,287
Research works printed but not linked: 1
- S Jiralerspong, 2009, Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breastcancer, J Clin Oncol, 27, 3297, 10.1200/JCO.2009.19.6410 · DOI · Paper page
Cited by
Sorted by citations
Epidemiology of Hepatocellular Carcinoma
McGlynn, K. A., Petrick, J. L., & El‐Serag, H. B. (2020) · Hepatology · doi:10.1002/hep.31288 · Cited by 2,200
Revisiting STAT3 signalling in cancer: new and unexpected biological functions
Yu, H., Lee, H., Herrmann, A., Buettner, R., & Jove, R. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3818 · Cited by 2,137
Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Tempero, M. A., Malafa, M. P., Al-Hawary, M. M., Behrman, S. W., Benson, A. B., Cardin, D. B., Chiorean, E. G., Chung, V. M., Czito, B. G., Chiaro, M. D., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0017 · Cited by 1,356
Tilg, H., Moschen, A. R., & Roden, M. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.147 · Cited by 1,002
Targeting Metabolism for Cancer Therapy
Luengo, A., Gui, D. Y., & Vander Heiden, M. G. (2017) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.08.028 · Cited by 971
Global Epidemiology of Hepatocellular Carcinoma
McGlynn, K. A., Petrick, J. L., & London, W. T. (2015) · Clinics in Liver Disease · doi:10.1016/j.cld.2015.01.001 · Cited by 938
Risk factors for endometrial cancer: An umbrella review of the literature
Raglan, O., Kalliala, I. E. J., Markozannes, G., Cividini, S., Gunter, M. J., Nautiyal, J., Gabra, H., Paraskevaidis, E. A., Martin‐Hirsch, P. L., Tsilidis, K. K., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31961 · Cited by 664
Yun, J., & Finkel, T. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.01.011 · Cited by 626
Metformin in Cancer Treatment and Prevention
Morales, D. R., & Morris, A. D. (2014) · Annual Review of Medicine · doi:10.1146/annurev-med-062613-093128 · Cited by 494
The quest to slow ageing through drug discovery
Partridge, L., Fuentealba, M., & Kennedy, B. K. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0067-7 · Cited by 468
Gandini, S., Puntoni, M., Heckman-Stoddard, B. M., Dunn, B. K., Ford, L., DeCensi, A., & Szabo, E. (2014) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-13-0424 · Cited by 457
Risk factors for pancreatic cancer: a summary review of meta-analytical studies
Maisonneuve, P., & Lowenfels, A. B. (2014) · International Journal of Epidemiology · doi:10.1093/ije/dyu240 · Cited by 465
Drug repurposing for cancer therapy
Xia, Y., Sun, M., Huang, H., & Jin, W.-L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01808-1 · Cited by 443
Bannister, C. A., Holden, S. E., Jenkins‐Jones, S., Morgan, C. L., Halcox, J. P., Schernthaner, G., Mukherjee, J., & Currie, C. J. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12354 · Cited by 356
Metformin in cancer prevention and therapy.
Kasznicki, J., Śliwińska, A., & Drzewoski, J. (2014) · PubMed Central · doi:10.3978/j.issn.2305-5839.2014.06.01 · Cited by 362
Hyperglycemia as a Risk Factor for Cancer Progression
Ryu, T. Y., Park, J., & Scherer, P. E. (2014) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2014.38.5.330 · Cited by 331
Sleire, L., Førde, H. E., Netland, I. A., Leiss, L., Skeie, B. S., & Enger, P. Ø. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.07.013 · Cited by 329
Repurposing metformin for cancer treatment: current clinical studies
Chae, Y. K., Arya, A., Malecek, M., Shin, D. S., Carneiro, B. A., Chandra, S., Kaplan, J. B., Kalyan, A., Altman, J. K., Platanias, L. C., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8194 · Cited by 328
Repurposing metformin for the prevention of cancer and cancer recurrence
Heckman‐Stoddard, B. M., DeCensi, A., Sahasrabuddhe, V. V., & Ford, L. G. (2017) · Diabetologia · doi:10.1007/s00125-017-4372-6 · Cited by 302
de Queiroz, E. A. I. F., Puukila, S., Eichler, R. A. D. S., Sampaio, S. C., Forsyth, H. L., Lees, S. J., Barbosa, A. M., Dekker, R. F. H., Fortes, Z. B., & Khaper, N. (2014) · PLoS ONE · doi:10.1371/journal.pone.0098207 · Cited by 291
Repurposing metformin: an old drug with new tricks in its binding pockets
Pryor, R., & Cabreiro, F. (2015) · Biochemical Journal · doi:10.1042/bj20150497 · Cited by 280
Mallik, R., & Chowdhury, T. A. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.05.023 · Cited by 270
Romero, R., Erez, O., Hüttemann, M., Maymon, E., Panaitescu, B., Conde-Agudelo, A., Pacora, P., Yoon, B. H., & Grossman, L. I. (2017) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2017.06.003 · Cited by 253
Dinis-Ribeiro, M. J., Libânio, D., Uchima, H., Spaander, M. C. W., Bornschein, J., Matysiak‐Budnik, T., Tziatzios, G., Santos‐Antunes, J., Areia, M., Chapelle, N., et al. (2025) · Endoscopy · doi:10.1055/a-2529-5025 · Cited by 234
Mechanism of antineoplastic activity of lonidamine
Nath, K., Guo, L., Nancolas, B., NELSON, D. S., Shestov, A. A., Lee, S., Roman, J., Zhou, R., Leeper, D. B., Halestrap, A. P., et al. (2016) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2016.08.001 · Cited by 219
Epidemiology of Bladder Cancer
Malats, N., & Real, F. X. (2015) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2014.10.001 · Cited by 196
Dissecting the Dual Role of AMPK in Cancer: From Experimental to Human Studies
Zadra, G., Batista, J. L., & Loda, M. F. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0068 · Cited by 202
Metformin in colorectal cancer: molecular mechanism, preclinical and clinical aspects
Kamarudin, M. N. A., Sarker, M. M. R., Zhou, J., & Parhar, I. S. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1495-2 · Cited by 191
Nowak-Sliwinska, P. M., Scapozza, L., & Altaba, A. R. I. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2019.04.005 · Cited by 188
Inhibition of Mitochondrial Complex II by the Anticancer Agent Lonidamine
Guo, L., Shestov, A. A., Worth, A. J., Nath, K., NELSON, D. S., Leeper, D. B., Glickson, J. D., & Blair, I. A. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.697516 · Cited by 187
Obesity and cancer: mechanistic insights from transdisciplinary studies
Allott, E. H., & Hursting, S. D. (2015) · Endocrine Related Cancer · doi:10.1530/erc-15-0400 · Cited by 187
Preventing Allograft Rejection by Targeting Immune Metabolism
Lee, C.-F., Lo, Y.-C., Cheng, C.-H., Furtmüller, G. J., Oh, B. C., Andrade‐Oliveira, V., Thomas, A. G., Bowman, C. E., Slusher, B. S., Wolfgang, M. J., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.09.036 · Cited by 185
González, N., Prieto, I., del Puerto‐Nevado, L., Portal‐Núñez, S., Ardura, J. A., Cortón, M., Fernández‐Fernández, B., Aguilera, Ó., Gómez‐Guerrero, C., Mas, S., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.14472 · Cited by 177
Afzal, M. Z., Mercado, R. R., & Shirai, K. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0375-1 · Cited by 173
Metformin Prevents Cisplatin-Induced Cognitive Impairment and Brain Damage in Mice
Zhou, W., Kavelaars, A., & Heijnen, C. J. (2016) · PLoS ONE · doi:10.1371/journal.pone.0151890 · Cited by 170
Pioglitazone and bladder cancer risk: a systematic review and meta‐analysis
Tang, H., Shi, W., Fu, S., Wang, T., Zhai, S., Song, Y., & Han, J. (2018) · Cancer Medicine · doi:10.1002/cam4.1354 · Cited by 162
Nutrition, dietary interventions and prostate cancer: the latest evidence
Lin, P., Aronson, W. J., & Freedland, S. J. (2015) · BMC Medicine · doi:10.1186/s12916-014-0234-y · Cited by 159
p53 and metabolism: from mechanism to therapeutics
Simabuco, F. M., Morale, M. G., Pavan, I. C. B., Morelli, A. P., Silva, F. R., & Tamura, R. E. (2018) · Oncotarget · doi:10.18632/oncotarget.25267 · Cited by 159
Navarro, C., Ortega, Á., Santeliz, R., Garrido, B., Chacín, M., Galbán, N., Vera, I., Sanctis, J. B. D., & Bermúdez, V. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061303 · Cited by 152
Qu, C., Zhang, W., Zheng, G., Zhang, Z., Yin, J., & He, Z. (2013) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-013-1845-x · Cited by 151
Drug-repositioning opportunities for cancer therapy: novel molecular targets for known compounds
Würth, R., Thellung, S., Bajetto, A., Mazzanti, M., Florio, T., & Barbieri, F. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.09.017 · Cited by 151
Wu, L., Zhu, J., Prokop, L. J., & Murad, M. H. (2015) · Scientific Reports · doi:10.1038/srep10147 · Cited by 144
Survival of Patients with Stage IV Lung Cancer with Diabetes Treated with Metformin
Lin, J. J., Gallagher, E. J., Sigel, K. M., Mhango, G., Galsky, M. D., Smith, C. B., LeRoith, D., & Wisnivesky, J. P. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201407-1395oc · Cited by 138
Schuler, K., Rambally, B. S., DiFurio, M. J., Sampey, B. P., Gehrig, P. A., Makowski, L., & Bae-Jump, V. L. (2014) · Cancer Medicine · doi:10.1002/cam4.353 · Cited by 137
Molecular Connections between Cancer Cell Metabolism and the Tumor Microenvironment
Justus, C., Sanderlin, E. J., & Yang, L. V. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160511055 · Cited by 139
The Potential Effect of Metformin on Cancer: An Umbrella Review
Yu, H., Zhong, X. Z., Gao, P., Shi, J., Wu, Z., Guo, Z., Wang, Z., & Song, Y. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00617 · Cited by 135
Molecular Mechanisms of Metformin for Diabetes and Cancer Treatment
Li, M., Li, X., Zhang, H., & Lü, Y. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.01039 · Cited by 125
Effects of metformin on endometrial cancer: Systematic review and meta-analysis
Meireles, C. G., Pereira, S. A., Valadares, L. P., Rêgo, D. F., Simeoni, L. A., Guerra, E. N. S., & Lofrano‐Porto, A. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.07.120 · Cited by 118
Pollak, M. (2014) · Nature Medicine · doi:10.1038/nm.3596 · Cited by 115
Hoong, C. W. S., & Chua, M. W. J. (2021) · Endocrinology · doi:10.1210/endocr/bqab079 · Cited by 112
Metformin as a geroprotector: experimental and clinical evidence
Piskovatska, V., Stefanyshyn, N., Storey, K. B., Vaiserman, A. M., & Lushchak, O. V. (2018) · Biogerontology · doi:10.1007/s10522-018-9773-5 · Cited by 111
Mitochondria in cancer: in the aspects of tumorigenesis and targeted therapy
Badrinath, N., & Yoo, S. Y. (2018) · Carcinogenesis · doi:10.1093/carcin/bgy148 · Cited by 112
Huang, X. L., Khan, M. I., Wang, J., Ali, R., Ali, S. W., Zahra, Q. U. A., Kazmi, A., Lolai, A., Huang, Y., Hussain, A., et al. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.03.075 · Cited by 108
Metformin: A Novel Biological Modifier of Tumor Response to Radiation Therapy
Koritzinsky, M. (2015) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2015.06.003 · Cited by 103
Liu, F., Yan, L., Wang, Z., Lu, Y., Chu, Y., Li, X., Liu, Y., Rui, D., Nie, S., & Xiang, H. (2017) · Oncotarget · doi:10.18632/oncotarget.13762 · Cited by 99
Triggle, C. R., & Ding, H. (2015) · Acta Physiologica · doi:10.1111/apha.12644 · Cited by 101
Kowall, B., Stang, A., Rathmann, W., & Kostev, K. (2015) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3823 · Cited by 100
Diabetes Mellitus and the Colon
Piper, M. S., & Saad, R. J. (2017) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-017-0151-1 · Cited by 99
Metformin: New Preparations and Nonglycemic Benefits
Fujita, Y., & Inagaki, N. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0829-8 · Cited by 91
Metformin and Cancer: Solutions to a Real-World Evidence Failure
Yu, O. H. Y., & Suissa, S. (2023) · Diabetes Care · doi:10.2337/dci22-0047 · Cited by 92
Afzal, M. Z., Dragnev, K. H., Sarwar, T., & Shirai, K. (2019) · Lung Cancer Management · doi:10.2217/lmt-2018-0016 · Cited by 90
Ferroni, P., Riondino, S., Buonomo, O., Palmirotta, R., Guadagni, F., & Roselli, M. (2015) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2015/183928 · Cited by 87
Effects of metformin on head and neck cancer: A systematic review
Rêgo, D. F., Pavan, L. M. C., Elias, S. T., Canto, G. D. L., & Guerra, E. N. S. (2015) · Oral Oncology · doi:10.1016/j.oraloncology.2015.01.007 · Cited by 88
Zhou, Y.-Y., Zhu, G.-Q., Liu, T., Zheng, J.-N., Cheng, Z., Zou, T.-T., Braddock, M., Fu, S.-W., & Zheng, M.-H. (2016) · Scientific Reports · doi:10.1038/srep33743 · Cited by 69
Guimarães, T. A., Farias, L. C., Santos, E. S., Fraga, C. A. D. C., Orsine, L. A., Teles, L. D. F., Feltenberger, J. D., de Jesus, S. F., de Souza, M. G., Santos, S. H. S., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10842 · Cited by 86
Metformin use and gynecological cancers: A novel treatment option emerging from drug repositioning
Gadducci, A., Biglia, N., Tana, R., Cosio, S., & Gallo, M. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.06.006 · Cited by 87
Current Status and Application of Metformin for Prostate Cancer: A Comprehensive Review
Ahn, H. K., Lee, Y. H., & Koo, K. C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228540 · Cited by 87
Samuel, S., Varghese, E., Kubatka, P., Triggle, C., & Büsselberg, D. (2019) · Biomolecules · doi:10.3390/biom9120846 · Cited by 81
The role of obesity in oesophageal cancer development
Long, E., & Beales, I. (2014) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x14538689 · Cited by 81
Metformin Reduces Thyroid Cancer Risk in Taiwanese Patients with Type 2 Diabetes
Tseng, C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109852 · Cited by 78
Yu, H., Yin, L., Jiang, X., Sun, X., Wu, J., Tian, H., Gao, X., & He, X. (2014) · PLoS ONE · doi:10.1371/journal.pone.0116327 · Cited by 75
Metformin may reduce breast cancer risk in Taiwanese women with type 2 diabetes
Tseng, C. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-2985-8 · Cited by 74
A pilot ‘window of opportunity’ neoadjuvant study of metformin in localised prostate cancer
Joshua, A. M., Zannella, V. E., Downes, M. R., Bowes, B., Hersey, K. M., Koritzinsky, M., Schwab, M. G., Hofmann, U., Evans, A., van der Kwast, T., et al. (2014) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2014.20 · Cited by 75
Wang, M., Hu, R., Wu, H., Pan, J., Gong, W., Guo, L., Zhong, J.-M., Fei, F.-R., & Yu, M. (2015) · Scientific Reports · doi:10.1038/srep11503 · Cited by 74
The role of the TOR pathway in mediating the link between nutrition and longevity
Lushchak, O., Strilbytska, O., Piskovatska, V., Storey, K. B., Koliada, A., & Vaiserman, A. (2017) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2017.03.005 · Cited by 73
Pereira, F. V., de Melo, A. C. L., Low, J. S., de Castro, Í. A., Braga, T. T., de Almeida, D. C., de Lima, A. G. U. B., Hiyane, M. I., Corrêa-Costa, M., Andrade‐Oliveira, V., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25380 · Cited by 75
Adaptive responses of androgen receptor signaling in castration-resistant prostate cancer
Perner, S., Cronauer, M. V., Schrader, A. J., Klocker, H., Čulig, Z., & Baniahmad, A. (2015) · Oncotarget · doi:10.18632/oncotarget.4689 · Cited by 71
Metformin and endometrial cancer risk in Chinese women with type 2 diabetes mellitus in Taiwan
Tseng, C. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.03.059 · Cited by 71
Metformin in Lung Cancer: Review of in Vitro and in Vivo Animal Studies
Yousef, M., & Tsiani, E. (2017) · Cancers · doi:10.3390/cancers9050045 · Cited by 75
Old drug, new trick: Repurposing metformin for gynecologic cancers?
Febbraro, T., Lengyel, E. R., & Romero, I. L. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.10.011 · Cited by 71
Pathophysiological mechanisms linking obesity and esophageal adenocarcinoma
Alexandre, L. (2014) · World Journal of Gastrointestinal Pathophysiology · doi:10.4291/wjgp.v5.i4.534 · Cited by 70
Mechanisms behind the link between obesity and gastrointestinal cancers
Tilg, H., & Moschen, A. R. (2014) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2014.07.006 · Cited by 70
Metformin: A Dual-Role Player in Cancer Treatment and Prevention
Galal, M. A., Al-Rimawi, M., Hajeer, A., Dahman, H., Alouch, S. S., & Aljada, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25074083 · Cited by 73
Prospective study of Type 2 diabetes mellitus, anti-diabetic drugs and risk of prostate cancer
Häggström, C., Hemelrijck, M. V., Zethelius, B., Robinson, D., Grundmark, B., Holmberg, L., Guðbjörnsdóttir, S., Garmo, H., & Stattin, P. E. (2016) · International Journal of Cancer · doi:10.1002/ijc.30480 · Cited by 69
Metformin reduces ovarian cancer risk in Taiwanese women with type 2 diabetes mellitus
Tseng, C. (2015) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2649 · Cited by 67
Shang, D., Ju, W., Guo, L., Yan-ju, X., Liu, L., & Lu, J. (2017) · International Journal of Oncology · doi:10.3892/ijo.2017.3950 · Cited by 68
Shao, R., Li, X., Feng, Y., Lin, J.-F., & Billig, H. (2014) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-33-41 · Cited by 66
Use of metformin and risk of kidney cancer in patients with type 2 diabetes
Tseng, C. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.09.027 · Cited by 67
Repurposing old drugs in oncology: Opportunities with clinical and regulatory challenges ahead
Shah, R. R., & Stonier, P. (2018) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12759 · Cited by 65
Raval, A. D., Thakker, D., Vyas, A., Salkini, M., Madhavan, S. S., & Sambamoorthi, U. (2015) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2014.52 · Cited by 64
Rozengurt, E. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00357 · Cited by 67
Ikhlas, S., & Ahmad, M. (2017) · Life Sciences · doi:10.1016/j.lfs.2017.07.029 · Cited by 66
A Cohort Study of Metformin and Colorectal Cancer Risk among Patients with Diabetes Mellitus
Bradley, M. C., Ferrara, A. M., Achacoso, N. S., Ehrlich, S. F., Quesenberry, C. P., & Habel, L. A. (2018) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-17-0424 · Cited by 64
Collins, K. K. (2014) · Diabetes Spectrum · doi:10.2337/diaspect.27.4.276 · Cited by 63
Ma, W., Chen, J., Meng, Y., Yang, J., Cui, Q., & Zhou, Y. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01336 · Cited by 64
Metformin enhances tamoxifen-mediated tumor growth inhibition in ER-positive breast carcinoma
Ma, J., Guo, Y. H., Chen, S., Zhong, C., Xue, Y., Zhang, Y., Lai, X., Wei, Y., Yu, S., Zhang, J., et al. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-172 · Cited by 63
Targeting cellular metabolism to reduce head and neck cancer growth
Yang, J., Guo, Y., Seo, W., Zhang, R., Lu, C., Wang, Y. E., Luo, L., Paul, B., Yan, W., Saxena, D. B., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-41523-4 · Cited by 64
Metformin as an adjuvant in breast cancer treatment
Roshan, M. H. K., Shing, Y. K., & Pace, N. P. (2019) · SAGE Open Medicine · doi:10.1177/2050312119865114 · Cited by 63
The Anti-Aging Mechanism of Metformin: From Molecular Insights to Clinical Applications
Zhang, T., Li-jun, Z., Makarczyk, M. J., Feng, P., & Zhang, J. (2025) · Molecules · doi:10.3390/molecules30040816 · Cited by 64
Riaz, M. A., Sak, A., Erol, Y. B., Groneberg, M., Thomale, J., & Stuschke, M. (2019) · Scientific Reports · doi:10.1038/s41598-018-38004-5 · Cited by 62
Metadata
- Authors
- Franciosi, M., Lucisano, G., Lapice, E., Strippoli, G. F. M., Pellegrini, F., & Nicolucci, A.
- Affiliations
- University of Naples Federico II (IT)
- The University of Sydney (AU)
- Corresponding author
- Franciosi, Monica
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-08-02
- Volume
- 8
- Issue
- 8
- Pages
- e71583
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3732236
- OpenAlex
- W2081540191
- Cited by
- 428
- References
- 89
- Citations by year
- 2026: 8 · 2025: 18 · 2024: 19 · 2023: 27 · 2022: 18 · 2021: 29 · 2020: 31 · 2019: 36 · 2018: 31 · 2017: 44 · 2016: 51 · 2015: 59 · 2014: 52 · 2013: 5
- FWCI
- 5.23
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Keywords
- type 2 diabetes, cancer risk, cancer mortality, liver cancer, colorectal cancer, pancreatic cancer, gastric cancer, esophageal cancer, site-specific cancer, chemoprevention, antidiabetic drugs, drug safety, randomized controlled trials, observational studies, breast cancer, lung cancer, ovarian cancer, prostate cancer, bladder cancer, kidney cancer, melanoma
- MeSH terms
- Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Metformin, Neoplasms, Risk Factors, Meta-Analysis as Topic, Randomized Controlled Trials as Topic, Diabetes Complications
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
